Tracleer(bosentan)
Bosentan, Stayveer, Tracleer (bosentan) is a small molecule pharmaceutical. Bosentan was first approved as Tracleer on 2001-11-20. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension and systemic scleroderma. The pharmaceutical is active against endothelin receptor type B. In addition, it is known to target endothelin-1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Bosentan, Tracleer (discontinued: Bosentan)
Drug Products
FDA
EMA
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BOSENTAN, TRACLEER, ACTELION | |||
| 2024-09-05 | ODE*, ODE-161 | ||
HCPCS
No data
Clinical
Clinical Trials
131 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | 4 | 15 | 10 | 3 | 31 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | 2 | 10 | 7 | 3 | 21 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | 3 | 10 | 3 | 2 | 18 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | — | 1 | 5 | 6 | 1 | 13 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 4 | 3 | 2 | 1 | 8 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 4 | 3 | 2 | 1 | 8 |
| Fibrosis | D005355 | — | — | — | 2 | 4 | 2 | — | 6 |
| Pulmonary fibrosis | D011658 | — | J84.10 | — | 2 | 4 | 2 | — | 6 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | 1 | 3 | 2 | — | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | 1 | 1 | — | 3 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | 3 | — | — | 3 |
| Ulcer | D014456 | MPATH_579 | — | — | — | 2 | — | — | 2 |
| Skin ulcer | D012883 | — | L98.4 | — | — | 2 | — | — | 2 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | — | — | 1 |
| Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | — | — | 1 | — | — | 1 |
| Connective tissue diseases | D003240 | EFO_1001986 | M35 | — | — | 1 | — | — | 1 |
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital heart defects | D006330 | — | Q24.9 | — | 1 | — | — | 1 | 2 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | 2 | — | — | — | 2 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | 1 | — | — | — | 1 |
| Tricuspid atresia | D018785 | — | — | — | 1 | — | — | — | 1 |
| Hypoplastic left heart syndrome | D018636 | — | Q23.4 | — | 1 | — | — | — | 1 |
| Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | — | — | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | — | — | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | 1 | — | — | — | 1 |
| Apnea | D001049 | — | R06.81 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | — | — | — | — | 1 | 1 |
| Necrosis | D009336 | — | — | — | — | — | — | 1 | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
| Univentricular heart | D000080039 | — | Q20.4 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bosentan |
| INN | bosentan |
| Description | Bosentan is a sulfonamide, a member of pyrimidines and a primary alcohol. It has a role as an antihypertensive agent and an endothelin receptor antagonist. |
| Classification | Small molecule |
| Drug class | endothelin receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO |
Identifiers
| PDB | — |
| CAS-ID | 147536-97-8 |
| RxCUI | 1468845 |
| ChEMBL ID | CHEMBL957 |
| ChEBI ID | 51450 |
| PubChem CID | 104865 |
| DrugBank | DB00559 |
| UNII ID | XUL93R30K2 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Tracleer – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,142 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tracleer
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
51,436 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use